ZA201600089B - Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations - Google Patents

Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations

Info

Publication number
ZA201600089B
ZA201600089B ZA2016/00089A ZA201600089A ZA201600089B ZA 201600089 B ZA201600089 B ZA 201600089B ZA 2016/00089 A ZA2016/00089 A ZA 2016/00089A ZA 201600089 A ZA201600089 A ZA 201600089A ZA 201600089 B ZA201600089 B ZA 201600089B
Authority
ZA
South Africa
Prior art keywords
peptidomimetics
peptides
treatments
cancer patient
combination uses
Prior art date
Application number
ZA2016/00089A
Other languages
English (en)
Inventor
Takumi Kawabe
Naoki Mine
Naoya Saito
Keiichi Sakakibara
Takuji Sato
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52141164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201600089(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Publication of ZA201600089B publication Critical patent/ZA201600089B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2016/00089A 2013-06-24 2016-01-06 Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations ZA201600089B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361838777P 2013-06-24 2013-06-24
PCT/IB2014/001579 WO2014207556A1 (en) 2013-06-24 2014-06-24 Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations

Publications (1)

Publication Number Publication Date
ZA201600089B true ZA201600089B (en) 2020-02-26

Family

ID=52141164

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/00089A ZA201600089B (en) 2013-06-24 2016-01-06 Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations

Country Status (27)

Country Link
US (1) US9221872B2 (de)
EP (1) EP3013351B1 (de)
JP (1) JP6401255B2 (de)
KR (1) KR102247493B1 (de)
CN (1) CN105324121A (de)
AU (1) AU2014300713B2 (de)
BR (1) BR112015032542A2 (de)
CA (1) CA2916136C (de)
CL (1) CL2015003704A1 (de)
CY (1) CY1122523T1 (de)
DK (1) DK3013351T3 (de)
ES (1) ES2765300T3 (de)
HR (1) HRP20192264T1 (de)
HU (1) HUE046873T2 (de)
IL (1) IL243266B (de)
LT (1) LT3013351T (de)
MX (1) MX366341B (de)
MY (1) MY182232A (de)
PH (1) PH12015502855B1 (de)
PL (1) PL3013351T3 (de)
PT (1) PT3013351T (de)
RS (1) RS60180B1 (de)
RU (1) RU2732440C2 (de)
SG (1) SG11201510490VA (de)
SI (1) SI3013351T1 (de)
WO (1) WO2014207556A1 (de)
ZA (1) ZA201600089B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
EP4091624A1 (de) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin-analoga und verwendungen davon
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
EP4378536A3 (de) 2014-07-17 2024-10-09 Protagonist Therapeutics, Inc. Orale peptidhemmer des interleukin-23-rezeptors und deren verwendung zur behandlung von entzündlichen darmerkrankungen
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
EP3201217A4 (de) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Neuartige cyclische monomer- und dimerpeptide mit integrin-antagonisten-aktivität
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
TWI805542B (zh) * 2015-10-23 2023-06-21 日商坎巴斯有限公司 用於癌症治療之肽及擬肽與t細胞活化劑及/或查核點抑制劑之組合
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN115925790A (zh) 2016-03-23 2023-04-07 领导医疗有限公司 用于合成α4β7肽拮抗剂的方法
CN109563144B (zh) 2016-06-01 2023-03-28 雅斯娜 化合物
EP4092038A1 (de) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioidagonistpeptide und verwendungen davon
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
KR20220044277A (ko) 2019-07-10 2022-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146441A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP4247403A4 (de) 2020-11-20 2024-12-11 JANSSEN Pharmaceutica NV Zusammensetzungen von peptidinhibitoren des interleukin-23-rezeptors
JP2024525732A (ja) 2021-07-14 2024-07-12 ヤンセン バイオテツク,インコーポレーテツド インターロイキン-23受容体の脂質化ペプチド阻害剤
CN116139251B (zh) * 2021-08-10 2025-04-22 昆明医科大学 一种具有提高免疫力和抗肿瘤以及延长寿命的多肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4041066B2 (ja) * 2002-01-17 2008-01-30 武田薬品工業株式会社 抗増殖活性を有し、そして/または核酸損傷剤を増大するペプチドおよびペプチド模倣物あるいは処置
JP4689274B2 (ja) * 2002-10-31 2011-05-25 リガンド・ファーマシューティカルズ・インコーポレイテッド 新規なシタラビン・モノホスフェートプロドラッグ
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
JP4705567B2 (ja) * 2003-06-25 2011-06-22 株式会社 キャンバス 免疫調整活性、抗炎症活性、および抗ウイルス活性を有するペプチドおよびペプチド模倣物
TW201000116A (en) 2008-05-14 2010-01-01 Takeda Pharmaceutical Peptide compound and use thereof

Also Published As

Publication number Publication date
MX2015017609A (es) 2016-04-15
HK1219905A1 (en) 2017-04-21
RS60180B1 (sr) 2020-06-30
KR20160021792A (ko) 2016-02-26
DK3013351T3 (da) 2020-01-27
CN105324121A (zh) 2016-02-10
ES2765300T3 (es) 2020-06-08
AU2014300713B2 (en) 2019-02-14
EP3013351A4 (de) 2017-03-01
NZ715285A (en) 2021-09-24
PH12015502855B1 (en) 2022-02-11
WO2014207556A1 (en) 2014-12-31
EP3013351A1 (de) 2016-05-04
EP3013351B1 (de) 2019-10-30
US20150056301A1 (en) 2015-02-26
MY182232A (en) 2021-01-18
CL2015003704A1 (es) 2016-07-29
IL243266B (en) 2019-11-28
PT3013351T (pt) 2020-01-17
KR102247493B1 (ko) 2021-04-30
RU2732440C2 (ru) 2020-09-16
IL243266A0 (en) 2016-03-31
SG11201510490VA (en) 2016-01-28
MX366341B (es) 2019-07-05
CA2916136A1 (en) 2014-12-31
PH12015502855A1 (en) 2016-04-04
RU2016101718A3 (de) 2018-03-01
JP2016522245A (ja) 2016-07-28
US9221872B2 (en) 2015-12-29
SI3013351T1 (sl) 2020-03-31
JP6401255B2 (ja) 2018-10-10
HUE046873T2 (hu) 2020-03-30
BR112015032542A2 (pt) 2017-07-25
RU2016101718A (ru) 2017-07-28
PL3013351T3 (pl) 2020-05-18
CA2916136C (en) 2022-10-18
AU2014300713A1 (en) 2016-01-21
HRP20192264T1 (hr) 2020-03-06
CY1122523T1 (el) 2021-01-27
LT3013351T (lt) 2020-01-10

Similar Documents

Publication Publication Date Title
ZA201600089B (en) Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations
IL276106A (en) Garp-binding proteins and their uses
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
IL242881B (en) A toxic substance for use in combination with radiation in cancer treatment
ZA201505735B (en) Cancer drug and uses
GB201304467D0 (en) Compound for use in protecting skin
GB201413104D0 (en) Use of ancillary devices in radiotherapy systems
PT3058936T (pt) Composição peptídica e respetivos usos
LT3065759T (lt) Imunosupresiniai agentai ir jų panaudojimo terapija
GB201318170D0 (en) Proteins with Diagnostic and Therapeutic Uses
PL3071192T3 (pl) Związek kurkufenol do zastosowania w leczeniu nowotworu
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
SG11201510468TA (en) Compositions and methods for use in oncology
GB201320992D0 (en) Complex and uses thereof
SG11201502584XA (en) Peptides and methods for treating cancer
GB201308753D0 (en) Compounds and their use in therapy
GB201304038D0 (en) Treated cells and therapeutic uses
IL243091B (en) Compositions and methods for use in oncology
EP2968398B8 (de) Modifiziertes hyaluronan und verwendungen davon bei der krebsbehandlung
GB2519829B (en) Methods for monitoring treatment response and relapse in breast cancer
GB201308217D0 (en) Compounds and their use in therapy
GB201322958D0 (en) Uses of oligouronates in cancer treatment
AU2013901916A0 (en) An Agent and Use Thereof in Therapy
GB201301640D0 (en) Methods and peptides
EP3006564A4 (de) Neues peptid und anwendung davon